264879-16-5

Basic information

• Product Name: 5-CHLORO-4-FLUORO-2-HYDROXY-BENZALDEHYDE
• Synonyms: 5-CHLORO-4-FLUORO-2-HYDROXY-BENZALDEHYDE
• CAS NO: 264879-16-5
• Molecular Formula: C₇H₄ClFO₂
• Molecular Weight: 174.56
• Mol File: 264879-16-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 245.1±35.0 °C(Predicted)
• Appearance: /
• Density: 1.508±0.06 g/cm3(Predicted)
• PKA: 6.75±0.23(Predicted)
• CAS DataBase Reference: 5-CHLORO-4-FLUORO-2-HYDROXY-BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-4-FLUORO-2-HYDROXY-BENZALDEHYDE(264879-16-5)
• EPA Substance Registry System: 5-CHLORO-4-FLUORO-2-HYDROXY-BENZALDEHYDE(264879-16-5)

Safety Data

• Hazardous Substances Data: 264879-16-5(Hazardous Substances Data)

Upstream product

• 75-75-2 methanesulfonic acid 
• 348-60-7 4-chloro-3-fluorophenol 
• 74-89-5 methylamine 
• 100-97-0 hexamethylenetetramine 

Downstream Products

• 1253195-46-8 2-(4-chloro-5-fluoro-2-formyl-phenoxy)-2-methyl-propionic acid methyl ester 

Relevant articles and documents

Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles

GPR40 has become a new potential therapeutic target for the treatment of diabetes due to its role in mediating the enhancement of glucose-stimulated insulin secretion in pancreatic β cells with a low risk of hypoglycemia. As an effort to extend the chemical space and identify structurally distinct GPR40 agonists with improved liver safety, a novel series of fused-ring phenyl propanoic acid analogues were designed. Comprehensive structure-activity relationship studies around novel scaffolds were conducted and led to several analogues exhibited potent GPR40 agonistic activities and high selectivity against other fatty acid receptors. Further evaluation of pharmacokinetic (PK) profiles and in vivo efficacy identified compound 40a with excellent PK properties and significant glucose-lowering efficacy during an oral glucose tolerance test. In addition, compound 40a displayed lower hepatobiliary transporter inhibition and favorable druggability. All results indicate that compound 40a is a promising candidate for further development.

Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models

A series of novel compounds with two halogen substituents have been designed and synthesized to further optimize the 2-phenylcyclopropylmethylamine scaffold in the quest for drug-like 5-HT2C agonists. Compound (+)-22a was identified as a potent

BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS

The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula (1). Wherein Z, X, R1, R2, R3, and R4 are as described in specification.